The early diagnosis of systemic sclerosis has been a major challenge for the scleroderma community in the past 50 years. The recent publication of the predictive value of the VEDOSS (Very Early Diagnosis of Systemic Sclerosis) criteria in the Lancet Rheumatology in December 2021 has provided an unprecedented insight in the early stages of the disease. This editorial discusses the main findings from this 2021 VEDOSS publication and highlights key unanswered questions to be proposed on the research agenda in very early systemic sclerosis.
LescoatACavalinCEhrlichR, et al. The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. Lancet Rheumatol2019; 1: e257–264.
2.
Bellando-RandoneSGaldoFDLepriG, et al. Progression of patients with Raynaud’s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol2021; 3: e834–843.
3.
van den HoogenFKhannaDFransenJ, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative: ACR/EULAR classification criteria for SSc. Arthritis Rheumat2013; 65: 2737–2747.
4.
AvouacJFransenJWalkerUA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis2011; 70(3): 476–481.
5.
DomsicRTGaoSLaffoonM, et al. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology2021; 60: 4662–4670.
6.
JaafarSLescoatAHuangS, et al. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthrit Res Therapy2021; 23: 170.
7.
Matucci-CerinicMKahalehBWigleyFM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum2013; 65(8): 1953–1962.
8.
AllanoreYDistlerOMatucci-CerinicM, et al. Review: defining a unified vascular phenotype in systemic sclerosis. Arthritis Rheumatol2018; 70(2): 162–170.
9.
Rubio-RivasMCorbellaXPestaña-FernándezM, et al. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clin Rheumatol2018; 37: 999–1009.
10.
TsouPSPalisocPJFlavahanNA, et al. Dissecting the cellular mechanism of prostacyclin analogue iloprost in reversing vascular dysfunction in scleroderma. Arthrit Rheumatol2021; 73: 520–529.
11.
JaegerVKWirzEGAllanoreY, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS ONE2016; 11(10): e0163894.
12.
LescoatAVargaJMatucci-CerinicM, et al. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs2021; 30(6): 635–652.
13.
LescoatARoofehDKuwanaM, et al. Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies. Clin Rev Allergy Immunol2021 Online ahead of print.
14.
ArbuckleMRMcClainMTRubertoneMV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med2003; 349: 1526–1533.
15.
HomerKLWarrenJKarayevD, et al. Performance of anti-topoisomerase I antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting. J Clin Rheumatol2020; 26(3): 115–118.
16.
LamBHAssassiSCharlesJ, et al. False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: a case series from a scleroderma referral center. Semin Arthritis Rheum2022; 56: 152052.
17.
NihtyanovaSISariAHarveyJC, et al. Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol2020; 72(3): 465–476.
18.
JohnsonSRSoowamberMLFransenJ, et al. There is a need for new systemic sclerosis subset criteria. Scand J Rheumatol2018; 47(1): 62–70.
19.
LeRoyECBlackCFleischmajerR, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol1988; 15(2): 202–205.
20.
LeRoyECMedsgerTA. Criteria for the classification of early systemic sclerosis. J. Rheumatol2001; 28: 1573–1576.
21.
LigonCBWigleyFM. Editorial: scleroderma: bringing a disease from black-and-white into technicolor. Arthrit Rheumatol2015; 67: 3101–3103.
22.
SobanskiVGiovannelliJAllanoreY, et al. Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis. Arthritis Rheumatol2019; 71(9): 1553–1570.
23.
HinchcliffMMahoneyJM. Towards a new classification of systemic sclerosis. Nat Rev Rheumatol2019; 15(8): 456–457.
24.
SureshSCharltonDSnellEK, et al. Development of pulmonary hypertension in over one-third of patients with Th/To antibody-positive scleroderma in long-term follow-up. Arthritis Rheumatol2022; 74: 1580–1587.
25.
BenyamineABertinDResseguierN, et al. Quantification of antifibrillarin (anti-U3 RNP) antibodies: a new insight for patients with systemic sclerosis. Diagnostics2021; 11: 1064.
26.
LazzaroniMGMarascoECampochiaroC, et al. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology2021; 60: 5028–5041.
27.
SobanskiVGiovannelliJLynchBM, et al. Characteristics and survival of Anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol2016; 68(2): 484–493.
28.
ElhaiMAvouacJWalkerUA, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis2016; 75(1): 163–169.
29.
RechJSchettG. Towards preventive treatment of rheumatoid arthritis. Lancet2022; 400: 253–255.
